Bioness Inc.

61 articles about Bioness Inc.

• Bioventus Acquires Bioness, Inc.

  3/30/2021

  Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has acquired Bioness, Inc . (“Bioness”), a global leader in neuromodulation and rehabilitation medical devices through its innovative peripheral nerve stimulation (“PNS”) therapy and premium rehabilitation solutions, for $45 million in up-front consideration, with up to $65 million of contingent consideration

• Bioness, Inc. Announces Commercial Launch of Next Generation Bioness Integrated Therapy System (BITS) Balance System for Rehabilitation Facilities

  10/19/2020

  Bioness, Inc., the leading provider of cutting-edge, clinically supported rehabilitation therapies, today announced the commercial launch of the new Bioness Integrated Therapy System (BITS) for Balance.

• Bioness Announces StimRouter Milestones at 2020 North American Neuromodulation Society's Annual Meeting

  1/21/2020

  Bioness, Inc., the leading provider of advanced, clinically supported medical devices for the treatment of chronic pain of peripheral nerve origin, today announced its attendance at the 2020 North American Neuromodulation Society's Annual Meeting (NANS) in Las Vegas, Nevada, January 23-26, 2020

• Bioness Announces Preliminary European Post-Approval Results of StimRouter® Neuromodulation System for the Treatment of Overactive Bladder at the 49th International Continence Society Annual Meeting

  9/3/2019

  Bioness, Inc., the leading provider of advanced, clinically supported medical devices for the treatment of chronic pain of peripheral nerve origin, is attending the 49th International Continence Society (ICS) Annual Meeting in Gothenburg, Sweden from 3-6 September 2019.

• Bioness Announces First Australian Implant of StimRouter® Neuromodulation System at Nambour Selangor Private Hospital

  5/13/2019

  Device now available in Australia for the management of chronic pain

• Bioness StimRouter® Neuromodulation System Receives European CE Mark Approval for the Treatment of Overactive Bladder (OAB)

  2/19/2019

  FDA-Approved StimRouter Continues to Improve the Lives of Chronic Pain Patients in the United States

• Bioness Introduces Key Updates to Rehabilitation Technology at the American Physical Therapy Association's Combined Sections Meeting

  1/22/2019

  Technology updates provide clinicians new training options for patients to maximize therapy sessions

• Bioness to Sponsor Educational Session on Peripheral Nerve Stimulation at 2019 North American Neuromodulation Society's Annual Meeting

  1/17/2019

  Clinical experts will share insights on present and future applications of neuromodulation technology

• Bioness Introduces First Peripheral Nerve Stimulation Registry with its StimRouter™ Neuromodulation System

  1/14/2019

  Bioness Inc., the leading provider of advanced, clinically supported medical devices for the treatment of chronic pain of peripheral nerve origin, has launched the first and only Patient Registry for peripheral nerve stimulation (PNS) using its StimRouter™ Neuromodulation System.

• Bioness Announces First Canadian Implants of StimRouter® Neuromodulation System at Women's College Hospital

  6/11/2018

  Bioness, Inc. announced the first successful implants of its StimRouter® Neuromodulation System for the treatment of chronic pain at Women's College Hospital in Toronto, Canada.

• Bioness to Exhibit at 2018 American Occupational Therapy Association Annual Conference and Expo

  4/17/2018

  Company will showcase full suite of rehabilitation and pain management technologies in booth #1835

• Bioness Receives FDA Clearance for myBioness™ iOS app for mobile control of the L300 Go™ System

  3/26/2018

  The myBioness is the first mobile app designed to provide control of the L300 Go™ System.

• Bioness Receives Health Canada Approval for StimRouter Neuromodulation System

  1/29/2018

  The Canadian medical device license provides approval to commercialize StimRouter and begin sales throughout Canada.

• Bioness StimRouter Neuromodulation System Eligible for Increased Medicare Reimbursements

  12/7/2017

  Effective January 1, 2018, providers will receive increased payments from Medicare for the StimRouter implant procedure, making the device an even more viable pain management option for patients and physicians nationwide.

• Bioness Announces Commercial Availability Of The L300 Go System To Healthcare Professionals

  8/30/2017

• Bioness Announces The Commercial Availability Of BITS Bedside & Mobile Configurations And Expanded International Distribution

  7/10/2017

• Bioness And Ottobock Announce Strategic European Distribution Partnership

  5/10/2017

• Bioness Receives CE Mark Certification For The L300 Go System

  4/25/2017

• Bioness StimRouter Neuromodulation System Receives Aetna Coverage

  3/27/2017

• Bioness Announces First European Implants For StimRouter Neuromodulation System

  2/22/2017